Less Toxic Cancer Therapies for Healthier Lives – Featured Research - Seattle Children's
Dr. Jay Sarthy aims to develop less toxic chemotherapy for high-risk leukemia, using aclarubicin, a promising but unpatentable anthracycline widely used in Asia. His lab's findings suggest aclarubicin is more effective and safer than doxorubicin, with potential to reduce long-term side effects. Sarthy plans FDA registration and clinical trials, needing philanthropic support due to lack of industry investment.
Reference News
Dr. Jay Sarthy aims to develop less toxic chemotherapy for high-risk leukemia, using aclarubicin, a promising but unpatentable anthracycline widely used in Asia. His lab's findings suggest aclarubicin is more effective and safer than doxorubicin, with potential to reduce long-term side effects. Sarthy plans FDA registration and clinical trials, needing philanthropic support due to lack of industry investment.